TY  - JOUR
AU  - Stulić, Miloš
AU  - Ćulafić, Đorđe
AU  - Obrenović, Radmila
AU  - Janković, Goran
AU  - Alempijević, Tamara
AU  - Stojković-Lalošević, Milica
AU  - Dostanić, Nataša
AU  - Vezmar-Kovačević, Sandra
AU  - Ćulafić, Milica
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3068
AB  - Background: Data suggest cystatin C (CysC) levels and hepatic artery resistive index (HARI) correspond to the progression of chronic liver disease. We aimed to evaluate the clinical significance of these parameters in assessment of fibrosis in patients with liver cirrhosis. Methods: The cross-sectional study included 63 patients with liver cirrhosis. A control group consisted of 30 age- and gender-matched healthy persons. Results: We confirmed significantly higher values of CysC in patients with cirrhosis compared to control group (p = 0.036). Average value of HARI in the examined group was increased (0.72 +/- 0.06) and there was the statistically significant difference compared to controls (0.66 +/- 0.03) (p  lt  0.001). We found statistically significant correlation between HARI and CysC in the study group. Analyzing the possibility of distinguishing healthy subjects from patients with fibrosis, we have found that the area under the curve is far greater in the HARI index than CysC. Comparison of CysC among Child-Pugh stages and correlation with a model for end-stage liver disease (MELD) score showed statistically significant results. Conclusion: We confirmed HARI is a more accurate parameter than CysC in discriminating healthy subjects from patients with fibrosis, while CysC could be a better indicator of the stage of liver cirrhosis.
PB  - MDPI, Basel
T2  - Medicina-Lithuania
T1  - The Clinical Importance of Cystatin C and Hepatic Artery Resistive Index in Liver Cirrhosis
VL  - 54
IS  - 3
DO  - 10.3390/medicina54030037
ER  - 

@article{
author = "Stulić, Miloš and Ćulafić, Đorđe and Obrenović, Radmila and Janković, Goran and Alempijević, Tamara and Stojković-Lalošević, Milica and Dostanić, Nataša and Vezmar-Kovačević, Sandra and Ćulafić, Milica",
year = "2018",
abstract = "Background: Data suggest cystatin C (CysC) levels and hepatic artery resistive index (HARI) correspond to the progression of chronic liver disease. We aimed to evaluate the clinical significance of these parameters in assessment of fibrosis in patients with liver cirrhosis. Methods: The cross-sectional study included 63 patients with liver cirrhosis. A control group consisted of 30 age- and gender-matched healthy persons. Results: We confirmed significantly higher values of CysC in patients with cirrhosis compared to control group (p = 0.036). Average value of HARI in the examined group was increased (0.72 +/- 0.06) and there was the statistically significant difference compared to controls (0.66 +/- 0.03) (p  lt  0.001). We found statistically significant correlation between HARI and CysC in the study group. Analyzing the possibility of distinguishing healthy subjects from patients with fibrosis, we have found that the area under the curve is far greater in the HARI index than CysC. Comparison of CysC among Child-Pugh stages and correlation with a model for end-stage liver disease (MELD) score showed statistically significant results. Conclusion: We confirmed HARI is a more accurate parameter than CysC in discriminating healthy subjects from patients with fibrosis, while CysC could be a better indicator of the stage of liver cirrhosis.",
publisher = "MDPI, Basel",
journal = "Medicina-Lithuania",
title = "The Clinical Importance of Cystatin C and Hepatic Artery Resistive Index in Liver Cirrhosis",
volume = "54",
number = "3",
doi = "10.3390/medicina54030037"
}

Stulić, M., Ćulafić, Đ., Obrenović, R., Janković, G., Alempijević, T., Stojković-Lalošević, M., Dostanić, N., Vezmar-Kovačević, S.,& Ćulafić, M.. (2018). The Clinical Importance of Cystatin C and Hepatic Artery Resistive Index in Liver Cirrhosis. in Medicina-Lithuania
MDPI, Basel., 54(3).
https://doi.org/10.3390/medicina54030037

Stulić M, Ćulafić Đ, Obrenović R, Janković G, Alempijević T, Stojković-Lalošević M, Dostanić N, Vezmar-Kovačević S, Ćulafić M. The Clinical Importance of Cystatin C and Hepatic Artery Resistive Index in Liver Cirrhosis. in Medicina-Lithuania. 2018;54(3).
doi:10.3390/medicina54030037 .

Stulić, Miloš, Ćulafić, Đorđe, Obrenović, Radmila, Janković, Goran, Alempijević, Tamara, Stojković-Lalošević, Milica, Dostanić, Nataša, Vezmar-Kovačević, Sandra, Ćulafić, Milica, "The Clinical Importance of Cystatin C and Hepatic Artery Resistive Index in Liver Cirrhosis" in Medicina-Lithuania, 54, no. 3 (2018),
https://doi.org/10.3390/medicina54030037 . .

TY  - JOUR
AU  - Alempijević, Tamara
AU  - Zec, Simon
AU  - Nikolić, Vladimir
AU  - Veljković, Aleksandar
AU  - Milivojević, Vladimir
AU  - Dopsaj, Violeta
AU  - Stanković, Sanja
AU  - Milosavljević, Tomica
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2670
AB  - Background & Aims: Acute-on-chronic liver failure (ACLF) is characterized by a rapid progression to multiple organ failure and is associated with a very high mortality rate of 50-90%. Novel therapies are being investigated such as Erythropoietin (EPO). The aim of this prospective cohort study was to analyse the value of EPO in predicting prognosis and determine which patients may benefit most from EPO therapy. Methods: According to the EASL-CLIF criteria, 104 consecutive patients were diagnosed with ACLF, and separated into two groups based on the type of insult: bleeding (Group A=31) or non-bleeding (Group B=73). In addition to a complete biochemical work-up and calculation of relevant prognostic scores, levels of EPO were measured on admission and correlated to the type of insult and final outcome. Results: Fifteen patients from Group A (mean age 60.32 +/- 9.29 years) had a lethal outcome and higher values of EPO on admission (319.26 +/- 326.58 mIU/ml) (p lt 0.005), compared to the 37 patients from Group B (mean age 59.9 +/- 10.19 years) with EPO levels at admission of 29.88 +/- 34.6 mIU/mL. In Group B, a cut-off EPO value of 30.65 mIU/mL had a sensitivity of 87.5% and a specificity 57.4% in predicting lethal outcome with an AUROC of 0.823. In Group A, a cut-off value of 229.95 mlU/mL had a sensitivity and specificity of 53.3% and 92.7%, respectively. The AUROC for this cut-off was 0.847. Conclusions: Erythropoietin is superior to the standard prognostic scores in predicting 28-day mortality. Lower levels of EPO were detected in patients without bleeding as an insult indicating a possible therapeutic benefit in these patients.
PB  - Medical Univ Press, Cluj-Napoca
T2  - Journal of Gastrointestinal and Liver Diseases
T1  - Erythropoietin in Predicting Prognosis in Patients with Acute-on-Chronic Liver Failure
VL  - 25
IS  - 4
SP  - 473
EP  - 479
DO  - 10.15403/jgld.2014.1121.254.jev
ER  - 

@article{
author = "Alempijević, Tamara and Zec, Simon and Nikolić, Vladimir and Veljković, Aleksandar and Milivojević, Vladimir and Dopsaj, Violeta and Stanković, Sanja and Milosavljević, Tomica",
year = "2016",
abstract = "Background & Aims: Acute-on-chronic liver failure (ACLF) is characterized by a rapid progression to multiple organ failure and is associated with a very high mortality rate of 50-90%. Novel therapies are being investigated such as Erythropoietin (EPO). The aim of this prospective cohort study was to analyse the value of EPO in predicting prognosis and determine which patients may benefit most from EPO therapy. Methods: According to the EASL-CLIF criteria, 104 consecutive patients were diagnosed with ACLF, and separated into two groups based on the type of insult: bleeding (Group A=31) or non-bleeding (Group B=73). In addition to a complete biochemical work-up and calculation of relevant prognostic scores, levels of EPO were measured on admission and correlated to the type of insult and final outcome. Results: Fifteen patients from Group A (mean age 60.32 +/- 9.29 years) had a lethal outcome and higher values of EPO on admission (319.26 +/- 326.58 mIU/ml) (p lt 0.005), compared to the 37 patients from Group B (mean age 59.9 +/- 10.19 years) with EPO levels at admission of 29.88 +/- 34.6 mIU/mL. In Group B, a cut-off EPO value of 30.65 mIU/mL had a sensitivity of 87.5% and a specificity 57.4% in predicting lethal outcome with an AUROC of 0.823. In Group A, a cut-off value of 229.95 mlU/mL had a sensitivity and specificity of 53.3% and 92.7%, respectively. The AUROC for this cut-off was 0.847. Conclusions: Erythropoietin is superior to the standard prognostic scores in predicting 28-day mortality. Lower levels of EPO were detected in patients without bleeding as an insult indicating a possible therapeutic benefit in these patients.",
publisher = "Medical Univ Press, Cluj-Napoca",
journal = "Journal of Gastrointestinal and Liver Diseases",
title = "Erythropoietin in Predicting Prognosis in Patients with Acute-on-Chronic Liver Failure",
volume = "25",
number = "4",
pages = "473-479",
doi = "10.15403/jgld.2014.1121.254.jev"
}

Alempijević, T., Zec, S., Nikolić, V., Veljković, A., Milivojević, V., Dopsaj, V., Stanković, S.,& Milosavljević, T.. (2016). Erythropoietin in Predicting Prognosis in Patients with Acute-on-Chronic Liver Failure. in Journal of Gastrointestinal and Liver Diseases
Medical Univ Press, Cluj-Napoca., 25(4), 473-479.
https://doi.org/10.15403/jgld.2014.1121.254.jev

Alempijević T, Zec S, Nikolić V, Veljković A, Milivojević V, Dopsaj V, Stanković S, Milosavljević T. Erythropoietin in Predicting Prognosis in Patients with Acute-on-Chronic Liver Failure. in Journal of Gastrointestinal and Liver Diseases. 2016;25(4):473-479.
doi:10.15403/jgld.2014.1121.254.jev .

Alempijević, Tamara, Zec, Simon, Nikolić, Vladimir, Veljković, Aleksandar, Milivojević, Vladimir, Dopsaj, Violeta, Stanković, Sanja, Milosavljević, Tomica, "Erythropoietin in Predicting Prognosis in Patients with Acute-on-Chronic Liver Failure" in Journal of Gastrointestinal and Liver Diseases, 25, no. 4 (2016):473-479,
https://doi.org/10.15403/jgld.2014.1121.254.jev . .

TY  - JOUR
AU  - Topić, Aleksandra
AU  - Alempijević, Tamara
AU  - Sokić-Milutinović, Aleksandra
AU  - Kovačević, Nada
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1185
AB  - Alpha-1-antitrypsin (AAT) is an important serine protease inhibitor in humans. Hereditary alpha-1-antitrypsin deficiency (AATD) affects lungs and liver. Liver disease caused by AATD in paediatric patients has been previously well documented. However, the association of liver disease with alpha-1-antitrypsin gene polymorphisms in adults is less clear. Therefore, we aimed to study AAT polymorphisms in adults with liver disease. We performed a case-control study. AAT polymorphisms were investigated by isoelectric focusing in 61 patients with liver cirrhosis and 9 patients with hepatocellular carcinoma. The control group consisted of 218 healthy blood donors. A significant deviation of observed and expected frequency of AAT phenotypes from Hardy-Weinberg equilibrium (chi-square = 34.77, df 11, P = 0.000) in the patient group was caused by a higher than expected frequency of Pi ZZ homozygotes (f = 0.0143 and f = 0.0005, respectively, P = 0.000). In addition, Pi M homozygotes were more frequent in patients than in controls (63% and 46%, respectively, P = 0.025). Our study results show that Pi ZZ homozygosity in adults could be associated with severe liver disease. Presence of Pi M homozygosity could be associated with liver disease via some mechanism different from Z allele-induced liver damage through accumulation of AAT polymers.
PB  - Taylor & Francis Ltd, Abingdon
T2  - Upsala Journal of Medical Sciences
T1  - Alpha-1-antitrypsin phenotypes in adult liver disease patients
VL  - 114
IS  - 4
SP  - 228
EP  - 234
DO  - 10.3109/03009730903243472
ER  - 

@article{
author = "Topić, Aleksandra and Alempijević, Tamara and Sokić-Milutinović, Aleksandra and Kovačević, Nada",
year = "2009",
abstract = "Alpha-1-antitrypsin (AAT) is an important serine protease inhibitor in humans. Hereditary alpha-1-antitrypsin deficiency (AATD) affects lungs and liver. Liver disease caused by AATD in paediatric patients has been previously well documented. However, the association of liver disease with alpha-1-antitrypsin gene polymorphisms in adults is less clear. Therefore, we aimed to study AAT polymorphisms in adults with liver disease. We performed a case-control study. AAT polymorphisms were investigated by isoelectric focusing in 61 patients with liver cirrhosis and 9 patients with hepatocellular carcinoma. The control group consisted of 218 healthy blood donors. A significant deviation of observed and expected frequency of AAT phenotypes from Hardy-Weinberg equilibrium (chi-square = 34.77, df 11, P = 0.000) in the patient group was caused by a higher than expected frequency of Pi ZZ homozygotes (f = 0.0143 and f = 0.0005, respectively, P = 0.000). In addition, Pi M homozygotes were more frequent in patients than in controls (63% and 46%, respectively, P = 0.025). Our study results show that Pi ZZ homozygosity in adults could be associated with severe liver disease. Presence of Pi M homozygosity could be associated with liver disease via some mechanism different from Z allele-induced liver damage through accumulation of AAT polymers.",
publisher = "Taylor & Francis Ltd, Abingdon",
journal = "Upsala Journal of Medical Sciences",
title = "Alpha-1-antitrypsin phenotypes in adult liver disease patients",
volume = "114",
number = "4",
pages = "228-234",
doi = "10.3109/03009730903243472"
}

Topić, A., Alempijević, T., Sokić-Milutinović, A.,& Kovačević, N.. (2009). Alpha-1-antitrypsin phenotypes in adult liver disease patients. in Upsala Journal of Medical Sciences
Taylor & Francis Ltd, Abingdon., 114(4), 228-234.
https://doi.org/10.3109/03009730903243472

Topić A, Alempijević T, Sokić-Milutinović A, Kovačević N. Alpha-1-antitrypsin phenotypes in adult liver disease patients. in Upsala Journal of Medical Sciences. 2009;114(4):228-234.
doi:10.3109/03009730903243472 .

Topić, Aleksandra, Alempijević, Tamara, Sokić-Milutinović, Aleksandra, Kovačević, Nada, "Alpha-1-antitrypsin phenotypes in adult liver disease patients" in Upsala Journal of Medical Sciences, 114, no. 4 (2009):228-234,
https://doi.org/10.3109/03009730903243472 . .